Wegovy demand cited; Lilly tops $1T

Novo Nordisk on September 7 published new late-stage data for semaglutide in children ages 6 to under 12, extending debate around how far GLP-1 medicines may move beyond their current labels. Eli Lilly, whose own GLP-1 franchise has driven investor demand, was valued at about $1.02 trillion as of September 4, according to market data. Regulators in the United States and Japan have also tightened attention on how GLP-1 drugs are sold, compounded and promoted as demand remains high. In India, court and patent developments have kept investors focused on when local drugmakers may widen access to semaglutide-based products. ### What did Novo Nordisk actually report on semaglutide this week? Novo Nordisk said on September 7 that 40.4% of children living with obesity who received once-weekly semaglutide plus lifestyle intervention achieved a body-mass index below the obesity threshold after 68 weeks, compared with 0% on placebo. The company said the phase 3 STEP Young trial covered children ages 6 to under 12 and that the safety profile was consistent with semaglutide use in adults and adolescents. The company also said semaglutide is not approved for that age group. Novo Nordisk published the result in its newsroom rather than as a regulatory decision, making the release a clinical update rather than a label expansion. ### Why is Eli Lilly part of the same market conversation? Eli Lilly’s market capitalization stood at $1.02 trillion on September 4, according to Stock Analysis data, keeping the company above the $1 trillion threshold that it first crossed in late 2025 as demand for its diabetes and obesity drugs lifted revenue and its share price. (novonordisk.com) Reuters Connect photographs from November 21, 2025, described Lilly as the first drugmaker to hit that valuation. Lilly’s rise has been tied to Mounjaro and Zepbound, while Novo Nordisk’s obesity franchise includes Wegovy. The two companies dominate much of the current GLP-1 discussion because semaglutide and tirzepatide demand has spilled beyond diabetes treatment into obesity care and, in some markets, into cosmetic or off-label use. (stockanalysis.com) ### Where does the compounded-versus-branded fight stand in the United States? The U.S. Food and Drug Administration said on April 1, 2026, that it was clarifying policies for compounders as national GLP-1 supply began to stabilize. The agency said compounded drugs qualify for statutory exemptions only under certain conditions, signaling closer scrutiny as branded supply constraints eased. (reutersconnect.com) The FDA has also flagged safety and fraud concerns around compounded and counterfeit semaglutide products. Its semaglutide safety pages say the agency is aware of fraudulent compounded semaglutide and tirzepatide marketed in the United States and has separately warned consumers about counterfeit Ozempic found in the supply chain. ### What are Japanese regulators and manufacturers warning about? (fda.gov) Japan’s health ministry issued a notice on June 16, 2026, calling for stricter measures to ensure proper use of GLP-1 receptor agonists and GIP/GLP-1 receptor agonists. The ministry said some medical institutions had been using the drugs for cosmetic or slimming purposes outside approved indications and said safety and efficacy had not been confirmed for such use. (fda.gov) A July 17, 2026, PMDA-linked notice from Novo Nordisk Pharma and Japan Eli Lilly said internet advertising had promoted off-label use for beauty, slimming and diet purposes. The notice said approved products listed in Japan had marketing authorization for type 2 diabetes only in the cases described there and warned that use outside approved methods could cause health harm. ### Why are Indian investors watching Dr. (mhlw.go.jp) Reddy’s and Sun Pharma? The Delhi High Court recorded undertakings in late 2025 that kept Sun Pharma from selling semaglutide in India until March 20, 2026, when Novo Nordisk’s patent was described as expiring, while allowing export-related activity in parallel litigation. Separate court reporting said Dr. Reddy’s won permission to manufacture semaglutide for export, with domestic sales restricted until the same March 2026 date. (pmda.go.jp) Those cases have made Dr. Reddy’s Laboratories and Sun Pharmaceutical Industries central to investor discussion about how quickly generic semaglutide competition could emerge in India after exclusivity barriers lift. The next concrete markers are regulatory filings, launch plans and any further court disclosures tied to semaglutide sales after March 2026. (livelawbiz.com)